UoLiverpool Confidence in Concept 2013

Lead Research Organisation: University of Liverpool

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
 
Description MICA: Development of a novel host blood test using TRanscripts to Identify bacterial Meningitis - TRIM test study
Amount £791,702 (GBP)
Funding ID MR/R015406/1 
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start 04/2019 
End 03/2022
 
Title ANTIVIRAL 4-(2-AMINO-6-HETEROCYLYL-9H-PURIN-9-YL)-2-CYCLOPENTENE-1 -METHANOL COMPOUNDS 
Description The present invention relates to certain antiviral compounds of formula I as defined herein that function as nucleoside reverse transcriptase inhibitors. The present invention also relates to processes for the preparation of these compounds, pharmaceutical compositions comprising them and to their use for the treatment of retroviral infections, and in particular their use in the treatment of HIV-1 virus. 
IP Reference WO2017021716 
Protection Patent application published
Year Protection Granted 2017
Licensed No
Impact Actively working with the IP team to identify a new industrial partner and they plan to re-apply for MRC-DPFS funding. In addition the team were successful in securing funding from Innovate UK (£35K - ICURe award) to perform market research and horizon scanning work to determine likely routes to market for the diagnostic assay. Feedback indicated interest from diagnostics companies in both Human and Veterinary markets.
 
Title DETECTION OF BACTERIAL INFECTION 
Description The present invention relates to methods of detecting and treating a bacterial infection, such as bacterial meningitis, and addresses the problem of misdiagnosis of bacterial infections. The medical use of antibacterial agents in the treatment of a bacterial infection in a subject identified by the methods of the invention is also described. The methods of the invention comprise assaying a sample from the subject to obtain data of the relative abundance of target molecules indicative of the expression of at least one gene pair, determining the presence or absence of a bacterial infection in the subject in dependence on the data, and optionally treating the subject with an antibacterial agent if required. 
IP Reference WO2017068347 
Protection Patent application published
Year Protection Granted 2017
Licensed No
Impact Various follow-on awards and approach by the Foundation for Innovative Diagnostics (FIND), Geneva. They want to undertake a collaborative study to assess host marker accuracy in blood to distinguish bacterial from viral infection among fever patients from lower middle-income countries. FIND has access to appropriate patient sample sets. A collaborative agreement is being drafted.
 
Title METHODS FOR PREDICTING RESPONSE TO ANTI-TNF THERAPY 
Description The present invention relates to a method for predicting the response of a patient suffering from an autoimmune or immune-mediated disorder to anti-TNF therapy based upon the expression of a Low Density Granulocyte gene or one or more interferon regulated biomarkers. Also provided is a kit for performing the invention, and related methods of treatment and monitoring response to treatment. 
IP Reference WO2017093750 
Protection Patent application published
Year Protection Granted 2017
Licensed No
Impact Pending.
 
Title PHARMACOLOGICALLY ACTIVE COMPOUNDS 
Description [origin: WO2015097475A1] The present invention relates to compounds of formula (I) shown below: wherein Q is as defined herein. The compounds of formula (I) act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them. 
IP Reference EP3087055 
Protection Patent granted
Year Protection Granted 2016
Licensed No
Impact We are currently in licensing negotiations (heads-of-terms stage) with two large pharmaceutical companies and in the process of contacting a suitable venture capital investor.
 
Title PHARMACOLOGICALLY ACTIVE COMPOUNDS 
Description wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them. 
IP Reference US2016318947 
Protection Patent granted
Year Protection Granted 2016
Licensed No
Impact We are currently in licensing negotiations (heads-of-terms stage) with two large pharmaceutical companies and in the process of contacting a suitable venture capital investor.